NRXP

NRX Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.390

+0.07(3.017%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.450

Open

2.370

VWAP

2.41

Vol

346.24K

Mkt Cap

41.32M

Low

2.3001

Amount

835.70K

EV/EBITDA(TTM)

Total Shares

10.70M

42.96M

EV/OCF(TTM)

P/S(TTM)

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic.

Get winning stock picks in minutes

1 Analyst Rating

653.14% Upside

Wall Street analysts forecast NRXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXP is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

653.14% Upside

Current: 2.390

Low

18.00

Averages

18.00

High

18.00

653.14% Upside

Current: 2.390

Low

18.00

Averages

18.00

High

18.00

BTIG

Thomas Schrader

Strong Buy

Initiates

$18

2025-04-02

Reason

BTIG

Thomas Schrader

Price Target

$18

2025-04-02

Initiates

Strong Buy

Reason

BTIG initiated coverage of NRx Pharmaceuticals with a Buy rating and $18 price target. NRx Pharmaceuticals is working broadly in suicidal ideation and behavior, a large area of unmet need that has seen essentially no improvement in treatment outcomes in 50 years, and is seeking to generate an FDA-approved version of IV ketamine to help standardize the treatment landscape, the analyst tells investors in a research note. The initial IV ketamine FDA submission package is supported by a collection of high-quality and controlled trials supporting the drug's activity in suicidal ideation and depressive symptoms, and BTIG sees this approach as reasonably likely to be enough for approval as the real-world evidence for this indication is significant and includes huge composite data sets collected across the current treatment landscape.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$31

2025-03-31

Reason

D. Boral Capital

Jason Kolbert

Price Target

$31

2025-03-31

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$31

2025-03-24

Reason

D. Boral Capital

Jason Kolbert

Price Target

$31

2025-03-24

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

$19

2025-03-20

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

$19

2025-03-20

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$31

2025-03-20

Reason

D. Boral Capital

Jason Kolbert

Price Target

$31

2025-03-20

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$31

2025-03-17

Reason

D. Boral Capital

Jason Kolbert

Price Target

$31

2025-03-17

Maintains

Strong Buy

Reason

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for NRX Pharmaceuticals Inc (NRXP.O) is 17.85, compared to its 5-year average forward P/E of -1.16. For a more detailed relative valuation and DCF analysis to assess NRX Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.16

Current PE

17.85

Overvalued PE

8.13

Undervalued PE

-10.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.59

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.77

Undervalued EV/EBITDA

-1.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.11

Current PS

0.71

Overvalued PS

0.39

Undervalued PS

-0.18

Financials

Annual

Quarterly

FY2025Q1

YoY :

-37.53%

-3.75M

Operating Profit

FY2025Q1

YoY :

-15.56%

-5.51M

Net Income after Tax

FY2025Q1

YoY :

-95.39%

-0.34

EPS - Diluted

FY2025Q1

YoY :

-5.20%

-3.48M

Free Cash Flow

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

46.8K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

46.8K

USD

Months

0-12

0.0

USD

Months

NRXP News & Events

Events Timeline

2025-08-11 (ET)

2025-08-11

08:05:05

NRx Pharmaceuticals granted FDA Fast Track designation for NRX-100

2025-08-08 (ET)

2025-08-08

08:05:26

HOPE Therapeutics, NRx Pharmaceuticals cleared to close Dura Medical acquisition

2025-08-04 (ET)

2025-08-04

08:11:24

NRx files Citizen Petition with FDA seeking removal of BZT from ketamine

News

9.0

08-11PRnewswire

PinnedNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

8.5

08-08PRnewswire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

9.0

08-04PRnewswire

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products